Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital
Rev. bras. hematol. hemoter
;
35(3): 174-179, jun. 2013. tab, graf
Article
in English
| LILACS
| ID: lil-681971
ABSTRACT
Objetive The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods:
A retrospective review was performed of 100 non-electronic records of patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package.Results:
At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response.Conclusion:
The population of this study obtained lower-than-expected therapeutic responses compared to other studies. .
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Piperazines
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Leukemia, Myeloid
/
Fusion Proteins, bcr-abl
/
Treatment Outcome
/
Medication Adherence
Limits:
Female
/
Humans
/
Male
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
Rev. bras. hematol. hemoter
Journal subject:
Hematology
Year:
2013
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Universidade Federal do Ceara/BR
Similar
MEDLINE
...
LILACS
LIS